BioNTech is a German vaccine company that can deliver its COVID 19 vaccines adapted to the Omicron BA. If approved by the regulatory approval, 4 5 sub variants can be made in October.
BioNTech plans to supply both vaccines in time for fall booster campaigns, along with its US partner Pfizer, the company said on Monday when it presented its figures for the first half of the year H 1 on Monday.
BioNTech's net profit went up to $5.37 billion euros US $5.48 billion, up from 3.92 billion euros in the same period last year, according to the company.
ALSO READ: Biden ends his isolation on recovery from COVID 19 rebound case.
Revenues in the first six months rose by 30 percent year-on- year and reached 9.57 billion euro, despite a slump in sales in the second quarter. BioNTech forecasts for the full fiscal year 2022 were given by BioNTech, with sales of its COVID 19 vaccines expected to range from 13 to 17 billion euros.
Ugur Sahin, CEO and Co-Founder of BioNTech, said our COVID 19 product pipeline includes variant-adapted and next-generation vaccine candidates, aimed at prolonged and broad protection.
The Omicron booster is used in over 100 million vaccine doses, based on the earlier BA. BioNTech has already produced 1 variant. The European Medicines Agency is awaiting the approval of the vaccine. The vaccine 4 5 has not been initiated yet.
After COVID shutdown, Chile's Easter Island reopens to tourists.
Around 85 percent of the 69.4 million adults in Germany aged 18 and older are vaccine-vaccinated against COVID 19. Nearly three in four people have received a booster shot, while just over 10 percent have received two booster shots, according to official figures.